Harpoon Therapeutics (HARP) Upgraded by Zacks Investment Research to “Hold”

Zacks Investment Research upgraded shares of Harpoon Therapeutics (NASDAQ:HARP) from a sell rating to a hold rating in a research note issued to investors on Tuesday morning, Zacks.com reports.

According to Zacks, “Harpoon Therapeutics Inc. is a clinical-stage immunotherapy company developing a novel class of T cell engagers which harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. Using its proprietary Tri-specific T cell Activating Construct(TM) platform, they are developing a pipeline of novel T cell engagers, focused on the treatment of solid tumors and hematologic malignancies. Harpoon Therapeutics Inc. is based in San Francisco, United States. “

HARP has been the topic of a number of other research reports. Wedbush began coverage on shares of Harpoon Therapeutics in a report on Tuesday, March 5th. They set an outperform rating and a $23.00 target price on the stock. Robert W. Baird began coverage on shares of Harpoon Therapeutics in a report on Monday, April 22nd. They set an outperform rating and a $25.00 target price on the stock. Svb Leerink restated an outperform rating on shares of Harpoon Therapeutics in a report on Tuesday, March 5th. Finally, Canaccord Genuity began coverage on shares of Harpoon Therapeutics in a report on Tuesday, March 5th. They set a buy rating and a $24.00 target price on the stock. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Harpoon Therapeutics has a consensus rating of Buy and a consensus price target of $24.00.

Shares of HARP stock opened at $11.46 on Tuesday. Harpoon Therapeutics has a 12 month low of $9.07 and a 12 month high of $17.85. The firm has a market cap of $279.25 million and a PE ratio of -0.45.

Harpoon Therapeutics (NASDAQ:HARP) last announced its earnings results on Thursday, March 14th. The company reported ($8.15) EPS for the quarter. The firm had revenue of $1.06 million for the quarter, compared to analysts’ expectations of $1.22 million. On average, sell-side analysts forecast that Harpoon Therapeutics will post -2.78 earnings per share for the current year.

Several hedge funds have recently made changes to their positions in HARP. California State Teachers Retirement System purchased a new position in shares of Harpoon Therapeutics in the 1st quarter worth about $38,000. BlackRock Inc. purchased a new position in shares of Harpoon Therapeutics in the 1st quarter worth about $879,000. Fosun International Ltd purchased a new position in shares of Harpoon Therapeutics in the 1st quarter worth about $3,062,000. MPM Asset Management LLC purchased a new position in shares of Harpoon Therapeutics in the 1st quarter worth about $39,796,000. Finally, Northern Trust Corp purchased a new position in shares of Harpoon Therapeutics in the 1st quarter worth about $309,000. Hedge funds and other institutional investors own 0.19% of the company’s stock.

Harpoon Therapeutics Company Profile

Harpoon Therapeutics, Inc, a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead TriTAC product candidate is HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer.

Further Reading: Quiet Period Expirations

Get a free copy of the Zacks research report on Harpoon Therapeutics (HARP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Harpoon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harpoon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.